BACKGROUND
Naturamed develops unique compounds extracted from specific strains of plant materials for improved natural treatment solutions for benign prostatic hyperplasia (BPH). Affecting nearly 50% of men over age 50, BPH is a nonmalignant progressive disease involving obstruction of the prostate gland.

The sophisticated extraction and purification processes produce NABIA, bio-active compounds that inhibit multiple known biological mechanisms causing BPH symptoms — without the side effects of common pharmaceutical drugs.
Naturamed has developed NABIA, a natural product for the treatment and prevention of BPH based on a well-known plant native to Israel that can be safely used in its whole dried form.

 

 

TECHNOLOGY
Conventional treatment methods with medication and surgery are problematic and costly. Some common side effects produced by drugs — loss of sleep, incontinence, impotence, sexual dysfunction, and drowsiness — have driven BPH patients to search for effective, natural treatment alternatives.

Naturamed’s unique compounds are extracted from specific strains of plant materials grown in a controlled environment. Naturamed’s NABIA compound acts as a combined alpha-blocker and 5-alpha reductase inhibitor. The compound’s unique ability to act against multiple mechanisms makes the Naturamed product a significantly more effective solution in the multibillion-dollar natural BPH treatment market. NABIA offers better therapeutic advantages, including multi-mechanism inhibitors, no side effects non-toxic high potency as compared to other natural treatments.

Dr. Harold Wiener, CEO, combines scientific and academic activities with extensive experience in business development and strategic research and development planning. He founded and built the infrastructure for many successful companies. Dr. Wiener received his Ph.D. in applied chemistry from the Hebrew University of Jerusalem.

Avi Gal, founder, has over 15 years’ experience in the pharmaceutical and life sciences industries. He holds a B.Sc. in mechanical engineering from the Technion–Israel Institute of Technology.

Irena Oleinik, chief scientist and founder, has been involved in numerous biotechnology R&D projects. She has an M.Sc. in biotechnology from the Moscow University for Chemistry and Technology.